Extended-release niacin/laropiprant improves endothelial function in patients after myocardial infarction

Heart and Vessels

Volumn 29, Issue 3, 2014, Pages 313-319

  Bregar, Urska ^a   Jug, Borut ^a   Keber, Irena ^a   Cevc, Matija ^a   Sebestjen, Miran ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Coronary artery disease; Endothelial function; Extended release niacin laropiprant; High density lipoprotein cholesterol

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT PLUS NICOTINIC ACID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; PLACEBO; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; DELAYED RELEASE FORMULATION; DRUG COMBINATION; INDOLE DERIVATIVE; MK-0524; NICOTINIC ACID;

ADULT; ARTERY DILATATION; ARTICLE; BLOOD VESSEL FUNCTION; BRACHIAL ARTERY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATIONAL STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG RELEASE; DYSLIPIDEMIA; ENDOTHELIAL PROGENITOR CELL; ENZYME ACTIVITY; EXTENDED DRUG RELEASE; FLOW MEDIATED BRACHIAL ARTERY DILATION; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HOT FLUSH; HUMAN; HYPEREMIA; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NITROGLYCERIN INDUCED BRACHIAL ARTERY DILATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR SMOOTH MUSCLE; BLOOD; DELAYED RELEASE FORMULATION; DRUG COMBINATION; DRUG EFFECTS; MIDDLE AGED; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; SLOVENIA; TIME; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ADULT; BIOLOGICAL MARKERS; BRACHIAL ARTERY; CHOLESTEROL, HDL; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; INDOLES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NIACIN; SLOVENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84905167398     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-013-0367-5     Document Type: Article

References (29)

1. Cholesterol Treatment Trialists' (CTT) Collaboration (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials. Lancet 376:1670-1681
2. Tobaru T, Seki A, Asano R, Sumiyoshi T, Hagiwara N (2012) Lipid-lowering and anti-inflammatory effect of ezetimibe in hyperlipidemic patients with coronary artery disease. Heart Vessels. doi:10.1007/s00380-012-0243-8
3. Castelli WP (1988) Cholesterol and lipids in the risk of coronary artery disease - the Framingham Heart Study. Can J Cardiol 4(Suppl):5A-10A
4. Assmann G, Schulte H, von Eckardstein A, Huang Y (1996) High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124(Suppl):S11-S20
5. Warnholtz A, Wild P, Ostad MA, Elsner V, Stieber F, Schinzel R, Walter U, Peetz D, Lackner K, Blankenberg S, Munzel T (2009) Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study. Atherosclerosis 204(1):216-221
6. Hamilton SJ, Chew GT, Davis TM, Watts GF (2010) Niacin improves small artery vasodilatory function and compliance in statin-treated type 2 diabetic patients. Diab Vasc Dis Res 7(4):296-299
7. Vaccari CS, Nagamia S, Thoenes M, Oguchi A, Hammoud R, Khan BV (2007) Efficacy of controlled-release niacin in treatment of metabolic syndrome: correlation to surrogate markers of atherosclerosis, vascular reactivity, and inflammation. J Clin Lipidol 1(6):605-613 (Pubitemid 350215512)
8. McCormack PL, Keating GM (2005) Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidemia. Drugs 65:2719-2740 (Pubitemid 43050961)
9. Canner PL, Berge KG, Wenger NK, Stammler J, Friedman L, Prineas RJ, Friedewald W (1986) Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardio 8:1245-1255 (Pubitemid 17208898)
10. Chapman MJ, Redfern JS, McGovern ME, Giral P (2010) Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther 126(3):314-345
11. Kuvin JT, Ramet ME, Patel AR, Pandian NG, Mendelsohn ME, Karas RH (2002) A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 144:165-172 (Pubitemid 34734771)
12. Benjo AM, Maranhao RC, Coimbra SR, Andrade AC, Favarato D, Molina MS, Brandizzi LI, da Luz PL (2006) Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment. Atherosclerosis 187:116-122 (Pubitemid 43817002)
13. Chapman MJ, Redfern JS, McGovern ME, Giral P (2010) Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther 126:314-345
14. Bruckert E, Labeuche J, Amarenco P (2010) Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 210:353-361
15. Nordestgaard BG, Chapman MJ, Kausik R, Boren J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen, Tokgözoglu L, Tybjærg-Hansen A, European Atherosclerosis Society Consensus Panel (2010) Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31:2844-2853
16. Friedwald WT, Levy RI, Frederickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 18:499-502
17. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340:1111-1115
18. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace AK (2004) Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110:3512-3517 (Pubitemid 39612564)
19. Villines TC, Stanek EJ, Devine PJ, Turco M, Miller M, Weissman NJ, Griffen L, Taylor AJ (2010) The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 55:2721-2726
20. Morgan JM, Carey CM, Lincoff A, Capizzi DM (2004) The effects of niacin on lipoprotein subclass distribution. Prev Cardiol 7(4):182-187
21. Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, Mueller M, Horváth T, Doerries C, Heinemann M, Flemmer S, Markowski A, Manes C, Bahr MJ, Haller H, von Eckardstein A, Drexler H, Landmesser U (2010) Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 121:110-122
22. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, Dzau VJ (1990) Impaired vasodilatation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 86:228-234 (Pubitemid 20226996)
23. Bays HE, Shah A, Dong Q, McCrary Sisk C, Maccubbin D (2011) Extended-release niacin/laropiprant lipid-altering consistency across patients subgroups. Int J Clin Pract 65:436-445
24. Maccubbin D, Bays HE, Olsson AG, Elinott V, Elis A, Mitcel Y, Sirah W, Betteridge A, Reyes R, Yu Q, Kuznetsova O, Sisk CM, Pasternak RC, Paolini JF (2008) Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolemia or mixed dyslipidemia. Int J Clin Pract 62:1959-1970
25. Bays HE, Shah A, Lin J, Sisk CM, Dong Q, Maccubbin D (2012) Consistency of extended-release niacin/laropiprant effects on Lp(a), non-HDL-C, Apo A1 and ApoB/ApoA1 ratio across patient subgroups. Am J Cardiovasc Drugs 12(3):197-206
26. Lamon-Fava S, Diffenderfer MR, Barrett H, Buchsbaum A, Nyaku M, Horvath KV, Asztalos BF, Otokozawa S, Ai M, Matthan NR, Lichtenstein AH, Dolnikowski GG, Schafer E (2008) Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-1 and Apo-B-containing lipoproteins. Arterioscler Thromb Vasc Biol 28:1672-1678
27. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L (2004) Effects of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study). Lancet 364:937-952 (Pubitemid 39208455)
28. Walldius G, Junger I, Holme I, Aastveit AH, Kolar W, Steiner E (2001) High apolipoprotein B, low apolipoprotein a-1, and improvement in prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358:2026-2033 (Pubitemid 34084825)
29. Van der Steeg WA, Boekhold S, Stein EA, El-Harchoui K, Stroes E, Sandhu MS, Wareham NJ, Jukema JW, Luben R, Zwinderman AH, Kastelein JJ, Khaw KT (2007) Role of the apolipoprotein B-apolipoprotein A-1 ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med 146:640-648 (Pubitemid 351650519)